Abstract
We have previously demonstrated that cancer pathogenesis can be simulated in silico by using a panel of circulating microRNAs (miRNAs) as biomarkers. Etiology of papillary thyroid carcinoma (PTC) was investigated from plasma/serum to find therapeutic targets for PTC, as miRNA panels could be used for thyroid cancer biomarkers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH (1995) Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinoma. Oncogene 10:1813–1821
Ding ZY, Huang YJ, Tang JD, Li G, Jiang PQ, Wu HT (2016) Silencing of hypoxia-inducible factor-1α promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWp9, VEGF and VEGFR2. Exp Ther Med 12:3735–3741. https://doi.org/10.3892/etm.2016.3826
Fabbri M, Valeri N, Calin GA (2009) MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. Carcinogenesis 30:912–917. https://doi.org/10.1093/carcin/bgp063
Franceschi S, Lessi F, Panebianco F, Tantillo E, La Ferla M, Menicagli M, Aretini P, Apollo A, Naccarato AG, Marchetti I, Mazzanti CM (2017) Loss of c-LIT expression in thyroid cancer cells. PLoS One 12:e0173913. https://doi.org/10.1371/journal.pone.0173913
Fujii YR (2017) The microRNA 2000: from HIV-1 to healthcare. Scientific Research Publishing, Inc., Irvine, CA
Fujii YR (2018) The quantum language of the microRNA gene and anti-cancer: with a dynamic computer simulation of human breast cancer drug resistance. Integr Mol Med 5:1–13. https://doi.org/10.15761/IMM.1000346
Fujii YR (2019a) Cancer simulation from stage minus one by quantum microRNA language: lung, colorectal and pancreatic cancers. Med One 4:e190023. https://doi.org/10.20900/mo.20190023
Fujii YR (2019b) Quantum microRNA network analysis in gastric and esophageal cancers: xenotropic plant microRNAs cure from cancerous paradox via Helicobacter pylori infection. Gastroenterol Hepatol Endosc 4:1–18. https://doi.org/10.15761/GHE.1000187
Fujii YR (2020) The quantum microRNA immunity in human virus-associated diseases: virtual reality of HBV, HCV and HIV-1 infection, and hepatocellular carcinogenesis with AI machine learning. Arch Clin Biomed Res 4:089–129. https://doi.org/10.26502/acbr.50170092
Fujii YR (2022a) Quantum microRNA surveillance against cancer: parallel dimensional analysis of integrated networks by quantum microRNA language in female genital neoplasms. In: Rezaei N (ed) Interdisciplinary Cancer Research. Springer Nature, New York, pp 1–24. https://doi.org/10.1007/16833_2022_4
Fujii YR (2022b) Quantum microRNA surveillance against bladder cancer: quantum miRNA language/artificial intelligence (MIRAI) etiology analysis from serum/plasma or urine miRNA data. In: Rezaei N (ed) Interdisciplinary Cancer Research. Springer Nature, New York. https://doi.org/10.1007/16833_2022_5
Fujii YR (2022c) Quantum microRNA immunity and hematopoietic malignancies: etiological analysis of leukemia and lymphoma by quantum microRNA language with artificial intelligence (MIRAI). In: Rezaei N (ed) Interdisciplinary Cancer Research. Springer Nature, New York. https://doi.org/10.1007/16833_2022_11
Ito Y, Kobayashi T, Takeda T, Komoike Y, Wakasugi E, Tamaki Y, Tsujimoto M, Matsuura N, Monden M (1996) Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues. Br J Cancer 74:1269–1274. https://doi.org/10.1038/bjc.1996.528
Jiang Y, Wang J, Chen J, Wang J, Xu J (2020) Construction and analysis of an aberrant lncRNA-miRNA-mRNA network associated with papillary thyroid cancer. Medicine 99:45 (e22705). https://doi.org/10.1097/MD.0000000000022705
Kang YY, Liu Y, Wang ML, Guo M, Wang Y, Cheng ZF (2017) Construction and analyses of the microRNA-target gene differential regulatory network in thyroid carcinoma. PLoS One 12:e0178331. https://doi.org/10.1371/journal.pone.0178331
Krashin E, Piekielko-Witkowska A, Ellis M, Ashur-Fabian O (2019) Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol 10:59. https://doi.org/10.3389/fendo.2019.00059
Liu Y, Khan S, Li L, ten Hagen TLM, Falahati M (2022) Molecular mechanisms of thyroid cancer: a competing endogenous RNA (ceRNA) point of view. Biomed Phramacother 146:112251. https://doi.org/10.1016/j.biopha.2021.112251
Matoba H, Sugano S, Yamaguchi N, Miyachi Y (1998) Expression of transforming growth factor-beta1 and transforming growth factor-beta type-II receptor mRNA in papillary thyroid carcinoma. Horm Metab Res 30:624–628. https://doi.org/10.1055/s-2007-978946
Mincione G, Carmela M, Di Marcantonio MC, Tarantelli C, D’Inzeo S, Nicolussi A, Nardi F, Donini CF, Coppa A (2011) EGF and TGF-β1 effects on thyroid function. J Thyroid Res 2011:431718. https://doi.org/10.4061/2011/431718
Mogilyansky E, Rigoutsos I (2013) The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 20:1603–1614. https://doi.org/10.1038/cdd.2013.125
Nan BY, Xiong GF, Zhao ZR, Gu X, Huang XS (2021) Comprehensive identification of potential crucial genes and miRNA-mRNA regulatory networks in papillary thyroid cancer. BioMed Res Inter 2021:6752141. https://doi.org/10.1155/2021/6752141
Nguyen QT, Lee EJ, Huang MG, Park YI, Khullar A, Plodkowski RA (2015) Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits 8:30–40
Peres KC, Teodoro L, Amaral LHP, Teixeira ES, Barreto IS, de Freitas LLL, Maxio V, Assumpção LVM, Bufalo NE, Ward LS (2021) Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis. Arch Endocrinol Metab 65:172–184. https://doi.org/10.20945/2359-3997000000330
Shafee N, Kaluz S, Ru N, Stanbridge E (2009) PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett 282:109–115. https://doi.org/10.1016/j.canlet.2009.03.004
Shi Y, Zou M, Farid NR, ST AI-S (1996) Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinoma. Br J Cancer 74:1336–1341. https://doi.org/10.1038/bjc.1996.546
Song Q, An Q, Niu B, Lu X, Zhang N, Cao X (2019) Role of miR-221/222 in tumor development and the underlying mechanism. J Oncol 2019:7252013. https://doi.org/10.1155/2019/7252013
Sun Y, Dia WR, Xia N (2020) Comprehensive analysis of lncRNA-mediated ceRNA network in papillary thyroid cancer. Eur Rev Med Pharmacol Sci 24:10003–10014. https://doi.org/10.26355/eurrev_202010_23214
Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru A, Yamashita S (2008) Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 99:1147–1154. https://doi.org/10.1111/j.1349-7006.2008.00800.x
Tell G, Pines A, Arturi F, Cesaratto L, Adamson E, Puppin C, Presta I, Russo D, Filetti S, Damante G (2004) Control of phosphatase and tensin homolog (PTEN) gene expression in normal and neoplastic thyroid cells. Endocrinologie 145:4660–4666. https://doi.org/10.1210/en.2004-0282
Tomei S, Mazzanti C, Marchetti I, Rossi L, Zavaglia K, Lessi F, Apollo A, Aretini P, Di Coscio G, Bevilacqua G (2012) C-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules. J Transl Med 10:7. https://doi.org/10.1186/1479-5876-10-7
Turco A, Coppa A, Aloe S, Baccheschi G, Morrone S, Zupi G, Colletta G (1999) Overexpression of transforming growth factor beta-type II receptor reduces tumorigenicity and metastatic potential of K-ras-transformed thyroid cells. Int J Cancer 80:85–91. https://doi.org/10.1002/(sici)1097-0215(19990105)80:1<85::aid-ijc17>3.0.co;2-p
Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA Jr, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ (2010) Thyroid carcinoma. J Natl Compr Cancer Netw 8:1228–1274. https://doi.org/10.6004/jnccn.2010.0093
Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, Fusco A (2007) MicroRNA (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 14:791–798. https://doi.org/10.1677/ERC-07-0129
Wang B, Jiang W, Zheng X, Han Y, Liu R (2022) Research on a weighted gene co-expression network analysis method for mining pathogenic genes in thyroid cancer. PLoS One 17:e0272403. https://doi.org/10.1371/journal.pone.0272403
Wang Z, Zhang H, He L, Dong W, Li J, Shan Z, Teng W (2013) Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma. Onco Targets Ther 6:281–287. https://doi.org/10.2147/OTT.S43014
Yu S, Liu X, Zhang Y, Li J, Chen S, Zheng H, Reng R, Zhang C, Chen J, Chen L (2016) Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules. Onco Targets Ther 7:84165–84177. https://doi.org/10.18632/oncotarget.12389
Zhang A, Wang C, Lu H, Chen X, Ba Y, Zhang C, Zhang CY (2019) Altered serum microRNA profile may serve as an auxiliary tool for discriminating aggressive thyroid carcinoma from nonaggressive thyroid cancer and benign thyroid nodules. Dis Markers 2019:3717683. https://doi.org/10.1155/2019/3717683
Zhang Y, Xu D, Pan J, Yang Z, Chen M, Han J, Zhang S, Sun L, Qiao H (2017) Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma. Oncol Lett 13:4252–4266. https://doi.org/10.3892/ol.2017.6028
Zhao M, Wang KJ, Tan Z, Zheng CM, Liang Z, Zhao JQ (2016) Identification of potential therapeutic targets for papillary thyroid carcinoma by bioinformatics analysis. Oncol Lett 11:51–58. https://doi.org/10.3892/ol.2015.3829
Author information
Authors and Affiliations
Ethics declarations
 The authors declare that there are no conflicts of interest.
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Fujii, Y.R. (2023). Thyroid Cancer: Quantum MicroRNA Language/Artificial Intelligence (MIRAI)-Based Etiologic Analysis of Thyroid Cancer by Serum/Plasma miRNA Panel Data. In: The MicroRNA Quantum Code Book. Springer, Singapore. https://doi.org/10.1007/978-981-19-8586-7_9
Download citation
DOI: https://doi.org/10.1007/978-981-19-8586-7_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-8585-0
Online ISBN: 978-981-19-8586-7
eBook Packages: MedicineMedicine (R0)